Yong T Lin

US Patent:

20100196885, Aug 5, 2010

Filed:

Jan 22, 2008

Appl. No.:

12/449124

Inventors:

Gerard M. Turino - New York NY, US
Yong Y. Lin - Bridgewater NJ, US
Shuren Ma - Cliffside Park NJ, US
Seymour Lieberman - New York NY, US

International Classification:

C12Q 1/68
C12Q 1/00
G01N 33/00
C12Q 1/02

US Classification:

435 6, 435 4, 436 96, 435 29

Abstract:

The present invention relates to methods of diagnosing and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.

US Patent:

20110318741, Dec 29, 2011

Filed:

Jun 15, 2011

Appl. No.:

13/161201

Inventors:

Peter H. SCHAFER - Somerset NJ, US
Yong Lin - Brooklyn NY, US
Donna Sutherland - Green Brook NJ, US

International Classification:

C12Q 1/68
G01N 33/566

US Classification:

435 611, 435 721, 435 724, 435 613, 435 612

Abstract:

Provided herein are the biomarkers for predicting or monitoring the efficacy of a treatment for psoriasis. The use of certain cell markers and mRNA levels as biomarkers to predict whether a psoriasis treatment is likely to be successful is also provided. Further, the expression of these genes or cell markers can be used to monitor progress of treatment effectiveness and patient compliance in psoriasis patients who are receiving treatment.

US Patent:

20130273586, Oct 17, 2013

Filed:

Mar 15, 2013

Appl. No.:

13/836332

Inventors:

Shuren Ma - Cliffside Park NJ, US
Yong Y. Lin - Bridgewater NJ, US
Seymour Leiberman - New York NY, US

International Classification:

G01N 27/62

US Classification:

435 23, 436 96, 435 29

Abstract:

The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.

US Patent:

20180172705, Jun 21, 2018

Filed:

Feb 5, 2018

Appl. No.:

15/888959

Inventors:

- New York NY, US
Shuren Ma - Cliffside Park NJ, US
Yong Y. Lin - Bridgewater NJ, US
Seymour Leiberman - , US

International Classification:

G01N 33/68
H01J 49/00
G01N 27/62
G01N 30/72

Abstract:

The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.

US Patent:

20160103138, Apr 14, 2016

Filed:

Apr 30, 2014

Appl. No.:

14/888075

Inventors:

Yong Y. LIN - Bridgewater NJ, US
Shuren MA - Cliffside Park NJ, US
Gerard M. TURINO - New York NY, US
Toyonobu USUKI - Tokyo, JP

International Classification:

G01N 33/68
A61K 38/57
G01N 30/72

Abstract:

The present invention provides, inter alia, methods for measuring the amount of a marker of elastic fiber injury in a sample. The methods include contacting a sample with a compound of formula (1) and carrying out mass spectrometry on the sample containing the compound of formula (1). Also provided are methods of diagnosing whether a subject has a disease characterized by elastic fiber injury, a method for improving the accuracy and precision of mass spectroscopy analysis of a marker of elastic fiber injury, and kits for determining, by mass spectrometry, the amount of a marker of elastic fiber injury in a sample from a subject. Further provided are methods for preventing the progression of the effects associated with alpha-1 antitrypsin deficiency (AATD) in a subject with normal lung function.

US Patent:

20150355193, Dec 10, 2015

Filed:

May 14, 2015

Appl. No.:

14/712811

Inventors:

- New York NY, US
Shuren Ma - Cliffside Park NJ, US
Yong Y Lin - Bridgewater NJ, US
Seymour Leiberman - , US

International Classification:

G01N 33/68
G01N 30/72
H01J 49/00

Abstract:

The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.